BriaCell Therapeutics Corp Ordinary Shares BCTX 深 滬
等待開盤 08-22 09:30:00 美东时间
0.6416
-0.049
-7.05%
華盛通- 最 高0.6889
- 今 開0.6872
- 成交量 66.05万股
- 最 低 0.6349
- 昨 收 0.6903
- 總市值 434.75万
- 52周最高 29.40
- 市盈率 靜 --
- 換手率 9.75%
- 52周最低 0.61
- 委 比 -66.67%
- 總股本 677.61万
- 歷史最高 186.058
- 量 比 1.88
- 振 幅 7.82%
- 歷史最低 0.6349
- 每 手 1
- 風險率 4.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BriaCell Announces 1-for-10 Share Consolidation To Maintain Nasdaq Listing, Effective August 25, 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that
今天 00:02
BriaCell Joins MSK's 2025 Therapeutics Accelerator to Fast-Track Cancer Immunotherapy
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
08-13 19:36
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
BriaCell Therapeutics Corp. announced its acceptance into Memorial Sloan Kettering Cancer Center’s 2025 Therapeutics Accelerator program to accelerate the clinical development of its Bria-OTS+ immunotherapy for multiple cancers, including breast and prostate cancer. MSK’s resources will support regulatory and manufacturing efforts, with both parties expressing confidence in the therapy’s potential to advance cancer care.
08-13 11:30
BriaCell Announces Proposed Effective Date of Share Consolidation
BriaCell Therapeutics Corp. announced the consolidation of its common shares on a 1:10 basis to maintain compliance with Nasdaq listing requirements. The consolidation, subject to TSX and Nasdaq approval, is expected to take effect on August 25, 2025, with post-consolidation shares trading starting on August 26. Fractional shares will be rounded up or canceled, and outstanding convertible securities will be adjusted proportionally. Post-consolida...
08-06 00:17
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
BriaCell Therapeutics has added UCLA Health Jonsson Comprehensive Cancer Center to its Phase 3 trial evaluating the Bria-IMT therapy in combination with a checkpoint inhibitor for advanced metastatic breast cancer. The trial compares this regimen with physician's choice. Interim analysis will assess 144 patient events, with overall survival as the primary endpoint. The trial builds on Phase 2 data showing promising survival outcomes and has recei...
07-31 11:30
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
BriaCell Therapeutics Corp. has been granted a New Zealand patent (No. 785587) for its whole-cell cancer immunotherapy technology, which focuses on selecting treatments based on HLA allele profile matching. The patent, valid until February 27, 2037, supports the company's precision medicine approach to improve cancer care outcomes. BriaCell plans to leverage this as part of its global strategy to expand its immunotherapy platform across various c...
07-30 11:30
BriaCell Unveils TILsRx Platform Aiming To Supercharge Immune Response Against Hard-To-Treat Cancers
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))), (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary,
07-29 19:34
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
BriaPro Therapeutics Corp., a subsidiary of BriaCell Therapeutics Corp., is developing the TILsRx platform to tackle immune suppression and T cell exhaustion, enhancing tumor-infiltrating lymphocyte activation. This multivalent technology targets multiple cancer and immune pathways, improving selectivity and effectiveness while reducing off-target effects. Early candidates include B7-H3 antibodies, with potential applications across various cance...
07-29 11:30
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
BriaCell Therapeutics Corp. announces two clinical data poster presentations at the ESMO Congress 2025 in Berlin: a Phase III trial comparing Bria-IMT + CPI to physician’s choice in advanced metastatic breast cancer and a feasibility study of Bria-IMT in late-stage MBC. Abstracts will be available online on October 13, 2025, and presentations will be posted on BriaCell’s website post-conference.
07-25 11:30
BriaCell Therapeutics Slide After Equity Offer
Unity Software(U.US) reported fourth-quarter financial results after the market...
07-16 03:41
